IRIDEX Stock Price, News & Analysis (NASDAQ:IRIX) $2.57 +0.19 (+7.98%) (As of 11/28/2023 ET) Add Compare Share Share Today's Range$2.30▼$2.5950-Day Range$1.90▼$3.2852-Week Range$1.31▼$3.48Volume77,698 shsAverage Volume50,444 shsMarket Capitalization$41.76 millionP/E RatioN/ADividend YieldN/APrice Target$2.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media IRIDEX MarketRank™ Stock AnalysisAnalyst Rating0.00 Rating ScoreUpside/Downside22.2% Downside$2.00 Price TargetShort InterestHealthy2.64% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.85Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.50) to ($0.42) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.0.83 out of 5 starsComputer And Technology Sector592nd out of 597 stocksElectromedical Equipment Industry22nd out of 22 stocks 0.0 Analyst's Opinion Price Target Upside/DownsideAccording to analysts' consensus price target of $2.00, IRIDEX has a forecasted downside of 22.2% from its current price of $2.57.Amount of Analyst CoverageIRIDEX has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.64% of the float of IRIDEX has been sold short.Short Interest Ratio / Days to CoverIRIDEX has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in IRIDEX has recently increased by 79.93%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldIRIDEX does not currently pay a dividend.Dividend GrowthIRIDEX does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IRIX. Previous Next 3.3 News and Social Media Coverage News SentimentIRIDEX has a news sentiment score of 1.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.65 average news sentiment score of Computer and Technology companies.News Coverage This WeekMarketBeat has tracked 3 news articles for IRIDEX this week, compared to 0 articles on an average week.Search InterestOnly 2 people have searched for IRIX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added IRIDEX to their MarketBeat watchlist in the last 30 days. This is a decrease of -89% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, IRIDEX insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.20% of the stock of IRIDEX is held by insiders.Percentage Held by InstitutionsOnly 23.95% of the stock of IRIDEX is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for IRIDEX are expected to grow in the coming year, from ($0.50) to ($0.42) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of IRIDEX is -5.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of IRIDEX is -5.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIRIDEX has a P/B Ratio of 2.38. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About IRIDEX Stock (NASDAQ:IRIX)IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.Read More IRIX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IRIX Stock News HeadlinesNovember 27, 2023 | finance.yahoo.comIridex Corporation Announces Successful Appeal for Revision of Recent Medicare LCDs to Provide Broader Coverage of CyclophotocoagulationNovember 17, 2023 | finanznachrichten.deIRIDEX Corporation: Iridex Reports Third Quarter 2023 Financial Results and Business UpdateNovember 29, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 14, 2023 | benzinga.comIridex: Q3 Earnings InsightsNovember 14, 2023 | finance.yahoo.comIridex Reports Third Quarter 2023 Financial Results and Business UpdateNovember 13, 2023 | finance.yahoo.comIridex to Host Third Quarter Financial Results Conference Call on November 14, 2023November 9, 2023 | morningstar.comIRIDEX Corp IRIXNovember 2, 2023 | msn.comIridex Reimbursement Chaos Presents Buying OpportunityNovember 29, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 1, 2023 | msn.comWall Street Set to Open Mixed Ahead of Federal Reserve MeetingNovember 1, 2023 | benzinga.comNasdaq Surges Over 100 Points Ahead Of Fed Decision; WeWork Shares PlungeNovember 1, 2023 | markets.businessinsider.comDow Gains Over 100 Points; Fed Leaves Interest Rates UnchangedNovember 1, 2023 | msn.comBYU, WE and IRIX among pre-market losersNovember 1, 2023 | benzinga.comUS Stocks Mixed; Private Sector Payrolls Increase Less Than ExpectedOctober 26, 2023 | finance.yahoo.comIridex to Report Third Quarter Financial Results on November 14, 2023October 10, 2023 | finance.yahoo.comIRIDEX's (NASDAQ:IRIX) growing losses don't faze investors as the stock surges 18% this past weekAugust 30, 2023 | finanznachrichten.deIRIDEX Corporation: Iridex Announces Strategic Review to Unlock Shareholder ValueAugust 29, 2023 | seekingalpha.comIridex announces review of strategic alternatives, stock risesAugust 29, 2023 | finance.yahoo.comIridex Announces Strategic Review to Unlock Shareholder ValueAugust 11, 2023 | markets.businessinsider.comIridex Reports Second Quarter 2023 Financial ResultsAugust 9, 2023 | markets.businessinsider.comIRIDEX earnings preview: what Wall Street is expectingAugust 9, 2023 | finance.yahoo.comWe Think IRIDEX (NASDAQ:IRIX) Needs To Drive Business Growth CarefullyJuly 28, 2023 | finance.yahoo.comIridex to Report Second Quarter Financial Results on August 10, 2023June 21, 2023 | finance.yahoo.comZacks Industry Outlook Highlights IPG Photonics and IRIDEXJune 8, 2023 | finance.yahoo.comIRIDEX Corporation's (NASDAQ:IRIX) Price Is Right But Growth Is LackingMay 18, 2023 | finance.yahoo.comIridex (IRIX) Is Attractively Priced Despite Fast-paced MomentumMay 11, 2023 | msn.comIridex: Q1 Earnings InsightsSee More Headlines Receive IRIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IRIDEX and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/11/2021Today11/28/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/14/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Electromedical equipment Sub-IndustryN/A SectorComputer and Technology Current SymbolNASDAQ:IRIX CUSIPN/A CIK1006045 Webwww.iridex.com Phone(650) 940-4700Fax650-940-4710Employees130Year Founded1989Price Target and Rating Average Stock Price Target$2.00 High Stock Price Target$2.00 Low Stock Price Target$2.00 Potential Upside/Downside-22.2%Consensus Rating Rating Score (0-4)0.00 Research Coverage0 Analysts Profitability EPS (Most Recent Fiscal Year)($0.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,550,000.00 Net Margins-14.21% Pretax Margin-14.13% Return on Equity-49.98% Return on Assets-19.36% Debt Debt-to-Equity RatioN/A Current Ratio2.64 Quick Ratio1.66 Sales & Book Value Annual Sales$56.97 million Price / Sales0.73 Cash FlowN/A Price / Cash FlowN/A Book Value$1.08 per share Price / Book2.38Miscellaneous Outstanding Shares16,250,000Free Float15,241,000Market Cap$41.76 million OptionableNot Optionable Beta0.88 Social Links 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. David I. Bruce (Age 64)President, CEO & Director Comp: $459.31kMr. Patrick Mercer (Age 51)Chief Operating Officer Comp: $385.51kMs. Leigh SalvoHead of Investor RelationsKey CompetitorsTriSalus Life SciencesNASDAQ:TLSIPAVmedNASDAQ:PAVMMovanoNASDAQ:MOVEVapothermNYSE:VAPOBeyond AirNASDAQ:XAIRView All CompetitorsInstitutional OwnershipWolverine Trading LLCBought 10,500 shares on 11/16/2023Ownership: 0.000%Acadian Asset Management LLCSold 21,051 shares on 11/13/2023Ownership: 0.177%AMH Equity LtdBought 306,282 shares on 11/6/2023Ownership: 3.925%Perkins Capital Management Inc.Sold 10,200 shares on 11/2/2023Ownership: 0.248%FNY Investment Advisers LLCBought 15 shares on 10/10/2023Ownership: 0.000%View All Institutional Transactions IRIX Stock Analysis - Frequently Asked Questions What is IRIDEX's stock price target for 2024? 0 analysts have issued 12-month target prices for IRIDEX's stock. Their IRIX share price targets range from $2.00 to $2.00. On average, they expect the company's share price to reach $2.00 in the next year. This suggests that the stock has a possible downside of 22.2%. View analysts price targets for IRIX or view top-rated stocks among Wall Street analysts. How have IRIX shares performed in 2023? IRIDEX's stock was trading at $2.01 at the beginning of the year. Since then, IRIX shares have increased by 27.9% and is now trading at $2.57. View the best growth stocks for 2023 here. Are investors shorting IRIDEX? IRIDEX saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 319,200 shares, an increase of 79.9% from the October 31st total of 177,400 shares. Based on an average trading volume of 129,600 shares, the days-to-cover ratio is presently 2.5 days. Approximately 2.6% of the company's shares are sold short. View IRIDEX's Short Interest. When is IRIDEX's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 14th 2024. View our IRIX earnings forecast. How were IRIDEX's earnings last quarter? IRIDEX Co. (NASDAQ:IRIX) announced its earnings results on Thursday, November, 11th. The medical equipment provider reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.01. The medical equipment provider had revenue of $13.26 million for the quarter, compared to the consensus estimate of $11.90 million. IRIDEX had a negative trailing twelve-month return on equity of 49.98% and a negative net margin of 14.21%. During the same quarter in the prior year, the company posted ($0.12) EPS. What is Theodore A. Boutacoff's approval rating as IRIDEX's CEO? 7 employees have rated IRIDEX Chief Executive Officer Theodore A. Boutacoff on Glassdoor.com. Theodore A. Boutacoff has an approval rating of 64% among the company's employees. What other stocks do shareholders of IRIDEX own? Based on aggregate information from My MarketBeat watchlists, some companies that other IRIDEX investors own include NVIDIA (NVDA), Trevena (TRVN), CTI BioPharma (CTIC), Agile Therapeutics (AGRX), Genocea Biosciences (GNCA), Idera Pharmaceuticals (IDRA), Lipocine (LPCN), Rigel Pharmaceuticals (RIGL) and SCYNEXIS (SCYX). Who are IRIDEX's major shareholders? IRIDEX's stock is owned by many different institutional and retail investors. Top institutional investors include AMH Equity Ltd (3.93%), Perkins Capital Management Inc. (0.25%), Acadian Asset Management LLC (0.18%), Wolverine Trading LLC (0.00%), FNY Investment Advisers LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Nandini Devi and Robert Earle Grove. View institutional ownership trends. How do I buy shares of IRIDEX? Shares of IRIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:IRIX) was last updated on 11/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IRIDEX Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.